New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
09:16 EDTHDSN, NVAX, ANGI, DMND, SEAC, RALY, HTZ, BTU, CMTL, GWPHOn The Fly: Pre-market Movers
HIGHER: Angie's List (ANGI), up 7% after shares upgraded at BofA Merrill Lynch... GW Pharmaceuticals (GWPH), up 7.5% after receiving Fast Track designation for Epidiolex... Comtech (CMTL), up 6% after Q3 earnings beat, raised FY14 outlook. LOWER: Hertz (HTZ), down 10% after warning its Q1 results are "likely to be below consensus," disclosing that errors were identified during its preparation of its financial statements and that certain statements must be restated... Rally Software (RALY), down 23% after downgraded at William Blair, Deutsche Bank and Needham following the company's Q1 results... Novavax (NVAX), down 7.5% after filing to sell $100M of common stock... SeaChange (SEAC), down 10% after reporting disappointing earnings, guidance... Diamond Foods (DMND), down 7.5% after reporting lower than expected Q3 results... Hudson Technologies (HDSN), down 6.5% after 6M share spot secondary offering of shares priced at $2.50... Peabody (BTU), down 2% after shares downgraded at Goldman.
News For HTZ;ANGI;GWPH;RALY;NVAX;CMTL;SEAC;HDSN;BTU;DMND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 21, 2015
07:14 EDTGWPHGW Pharmaceuticals initiates second Phase 3 trial for Epidiolex
GW Pharmaceuticals announced that it has initiated the second Phase 3 clinical trial of Epidiolex for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. This follows GW's recent announcement of the commencement of the first Phase 3 clinical trial of Epidiolex in Dravet syndrome. GW expects to complete patient recruitment into this second trial in 2015 and to report top-line results in early 2016.
April 20, 2015
10:31 EDTANGIAngie's List announces partnership with On Deck Capital
Angie's List (ANGI) announced plans to team with On Deck Capital (ONDK) to offer financing to its service providers. As part of this agreement, service providers on Angie’s List will have access to OnDeck’s loans for up to $250,000. Qualifying service providers can use their loans to invest in their business’ growth, manage cash flow or finance their Angie’s List subscriptions.
10:29 EDTGWPHFly Watch: Added data on marijuana-derived epilepsy drug coming this week
GW Pharmaceuticals (GWPH) is expected to report additional results of a Phase III trial of its Epidiolex drug at the American Academy of Neurology's annual meeting on April 22. BACKGROUND: Made from cannabidiol, a non-psychoactive compound in marijuana, Epidolex is being tested as a treatment for certain forms of childhood epilepsy. Some data from the study was released on April 13 by the American Academy of Neurology, or AAN. That data was from physician-led FDA authorized Epidiolex "expanded access" programs for children and young adults with treatment-resistant epilepsy that have exhausted available treatment options, GW Pharmaceuticals stated. ANALYST TAKE: The risk/reward ratio for GW's stock is positive heading into the release of additional data on April 22, Leerink analyst Paul Matteis wrote in a note to investors earlier today. Investors are likely focused on three data points within the additional information, namely response rate data, whether the media overall seizure reduction differs from an October trial report when it was 36%, and the degree to which seizure reductions are sustained beyond 12 weeks. Given the study's lack of a placebo arm, investors may be most focused on the seizure reductions, as this is seen as a good indication as to whether controlled Phase III studies will be successful, wrote Matteis. Experts say that Epidiolex may be used to treat additional types of epliepsy if the Phase III data is positive, given its efficacy in difficult to treat patients and its superior safety profile compared with other epilepsy treatments, the analyst stated. The data already released from the latest study showed a "much greater" magnitude of overall seizure reduction than in the October update and a "consistent, robust effect" in larger samples of pediatric epilepsy patients, wrote Matteis, who raised his estimates of Epidiolex peak market penetrations and raised his price target on the stock to $120 from $102 while keeping an Outperform rating on the shares. PRICE ACTION: Shares of GW Pharmaceuticals are down $2, or 1.75%, to %112 per share in early trading. The stock has gained about 65% over the last six months.
10:00 EDTCMTLComtech received $1.3M order for satellite modems
Subscribe for More Information
08:48 EDTANGIAngie's List announces plans to team with On Deck Capital
Angie's List (ANGI) announced plans to team with OnDeck Capital (ONDK), a platform for small business loans, to offer financing to its service providers. As part of this agreement, service providers on Angie’s List will have access to OnDeck’s loans for up to $250,000. Qualifying service providers can use their loans to invest in their business’ growth, manage cash flow or finance their Angie’s List subscriptions.
08:20 EDTHTZThrifty Car Rental expands to Singapore
Subscribe for More Information
April 17, 2015
06:46 EDTBTUCourt looks poised to deny challenge to coal emissions rule, NY Times says
A federal appeals court seemed inclined to dismiss a lawsuit challenging the EPA's rule restricting carbon emissions from coal-fired power plants, The New York Times reported yesterday. Publicly traded companies in the coal space include Alliance Resource Partners (ARLP), Alpha Natural (ANR), Arch Coal (ACI), CONSOL (CNX), Cloud Peak (CLD), Peabody (BTU) and Walter Energy (WLT). Reference Link
April 15, 2015
12:38 EDTANGIAngie's List jumps as analysts weigh in on what's next after CEO resignation
Subscribe for More Information
11:22 EDTANGIAngie's List remains an acquisition target, says Wunderlich
Subscribe for More Information
10:59 EDTANGIAngie's List likely to look for turnaround CEO, says Piper Jaffray
Subscribe for More Information
09:13 EDTANGIAngie's List up 14.8% after announcing CEO departure, FY15 guidance
Subscribe for More Information
09:13 EDTANGIAngie's List backs FY15 revenue guidance of $357M-$363M, consensus $360M
Subscribe for More Information
08:46 EDTANGIAngie's List announces planned departure of CEO William Oesterle
Subscribe for More Information
April 14, 2015
08:38 EDTGWPHGW Pharmaceuticals price target raised to $120 from $102 at Leerink
Leerink analyst Paul Matteis raised his price target for shares of GW Pharmaceuticals to $120 after the American Academy of Neurology disclosed updated Epidiolex data from 137 patients. Matteis calls the data better than expectations saying they showed a "much greater" magnitude of overall seizure reduction than in the October update and a "consistent, robust effect" in larger samples of Dravet and Lennox Gastaut patients. He now assumes higher Epidiolex peak market penetrations and more use in the broader refractory pediatric epilepsy population. The analyst reiterates an Outperform rating on GW Pharmaceuticals. The stock closed yesterday at $96.18 and is trading up $7.87 to $104.05 in premarket trading.
07:25 EDTGWPHGW Pharmaceuticals undervalued based on Epidiolex potential, says Cowen
Subscribe for More Information
April 13, 2015
16:09 EDTGWPHGW Pharmaceuticals notes new Epidiolex data released by AAN
GW Pharmaceuticals noted that the American Academy of Neurology, or AAN, issued a press release today on GW's investigational medicine, Epidiolex. Data in the AAN release are from physician-led FDA authorized Epidiolex "expanded access" programs for children and young adults with treatment-resistant epilepsy that have exhausted available treatment options. The data provide treatment effect information on a total of 137 patients who have at least 12 weeks of Epidiolex exposure. Safety data is provided on 213 patients, representing these 137 patients plus additional patients still in their first 12 weeks of treatment. Additional data will be presented in a poster at the AAN Annual Meeting on 22 April at 6.15pm EDT, at which time GW will make an additional disclosure.
13:34 EDTHDSNHudson Technologies management to meet with Craig-Hallum
Subscribe for More Information
10:00 EDTRALYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:55 EDTSEACSeaChange still seen by Brean Capital as potential acquisition target
Subscribe for More Information
07:12 EDTRALYRally Software downgraded to Equal Weight from Overweight at Stephens
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use